Results 191 to 200 of about 1,669,562 (240)

Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy. [PDF]

Cancer Control
Sandoval ML, Rishi A, Latifi K, Grass GD, Torres-Roca J, Rosenberg SA, Yamoah K, Johnstone PAS.   +7 more
europepmc   +1 more source

Optimal Control‐Based RF Pulses Versus Classical Motion‐Encoding Strategies for In Vivo Hepatic MR Elastography Across Multiple Excitation Frequencies in Mice: Reproducibility Assessment

NMR in Biomedicine, Volume 39, Issue 10, October 2026.
Optimal control (OC)–based motion encoding doubles SNR in vivo in murine hepatic MRE by eliminating motion‐encoding gradients and enabling shorter echo times. Quantitative liver stiffness measurements remain consistent with conventional MEG‐MRE across multiple excitation frequencies, supporting longitudinal studies and clinical translation ...
Tiffany Bakir‐Ageron, Pilar Sango‐Solanas, Eric Van Reeth, Denis Grenier, Kevin Tse Ve Koon, Olivier Beuf   +5 more
wiley   +1 more source

A Reproducible MRI‐Based Pipeline for Longitudinal Tracking of Laser‐Assisted Bioprinted Cells in Three‐Dimensional Constructs

NMR in Biomedicine, Volume 39, Issue 10, October 2026.
Laser‐assisted bioprinting was used to deposit iron oxide‐labelled endothelial cells in predefined patterns onto SCAP‐seeded gelatin biopapers to assemble multilayer constructs of increasing thickness. T2*‐weighted MRI monitored constructs for up to 35 days.
Mina Medojević, Charles Handschin, Ayako Washio, Malou Lea, Laurence Dallet, Aleksandar Jakovljević, Emeline J. Ribot, Olivia Kérourédan   +7 more
wiley   +1 more source

Case report: Intrafraction dose-guided tracking for gastrointestinal organ-at-risk isotoxicity delivery on an MR-guided radiotherapy system. [PDF]

Front Oncol
Yarlagadda S, Weiss Y, Chuong MD, Bassiri N, Gutierrez AN, Kotecha R, Mehta MP, Mittauer KE.   +7 more
europepmc   +1 more source

Characterization of an inorganic scintillator for small-field dosimetry in MR-guided radiotherapy. [PDF]

J Appl Clin Med Phys, 2020
Cusumano D, Placidi L, D'Agostino E, Boldrini L, Menna S, Valentini V, De Spirito M, Azario L.   +7 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Patient expectation and experience of MR-guided radiotherapy using a 1.5T MR-Linac. [PDF]

Tech Innov Patient Support Radiat Oncol
de Mol van Otterloo SR, Westerhoff JM, Leer T, Rutgers RHA, Meijers LTC, Daamen LA, Intven MPW, Verkooijen HM.   +7 more
europepmc   +1 more source

Cost‐effectiveness analysis of total intravenous vs. inhalation anaesthesia among adults aged ≥ 50 y undergoing major non‐cardiac surgery

Anaesthesia, Volume 81, Issue 10, Page 1378-1385, October 2026.
Summary Introduction Total intravenous and inhalational anaesthesia are used widely to maintain general anaesthesia for major non‐cardiac surgery, yet their comparative cost‐effectiveness remains uncertain. The VITAL trial evaluated clinical outcomes, showing no difference in days alive and at home at 30 days.
Samuel Frempong, Rebecca Kandiyali, James Mason, Louise Hiller, Janet Dunn, Katie Booth, Ramani Moonesinghe, Rupert Pearse, Ben Shelley, Shaman Jhanji, Joyce Yeung, on behalf of the VITAL Trial Team   +11 more
wiley   +1 more source

Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer. [PDF]

Front Oncol
Fink CA, Buchele C, Baumann L, Liermann J, Hoegen P, Ristau J, Regnery S, Sandrini E, König L, Rippke C, Bonekamp D, Schlemmer HP, Debus J, Koerber SA, Klüter S, Hörner-Rieber J.   +15 more
europepmc   +1 more source

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study

BJU International, Volume 138, Issue 4, Page 600-606, October 2026.
Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53.
Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, Alexandra O. Sokolova, Erika M. Wolff, Daniel W. Lin   +12 more
wiley   +1 more source